Docket No. 4439-4028

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:		.: 10/518,870	Confirmation No.:	5652			
Applicant(s):		t(s): SHICHIRI, et al.	Group Art Unit: Examiner:	1614 TBA			
Filed:		August 29, 2005	Examiner.	IDA			
For:			Customer No.: 27123 NOVEL USE OF ANSAMYCIN ANTIBIOTICS AND METHOD OF SCREENIN NOVEL ANGIOGENESIS INHIBITOR				
		SUPPLEMENTAL INFORMATION	ON DISCLOSURE ST	ATEMENT			
Co. P.C	mmiss	Amendment ioner for Patents 1450 ia, VA 22313-1450					
Sir	:						
ma The	de of r	This Information Disclosure States 97 and 1.98. The items listed on Form ecord to assist the Patent and Trademarlainer is respectfully requested to fully coning. For each of the following items listed on tin the English language, an English thereof or a concise explanation of the	PTO-1449, a copy of v x Office in its examinat onsider the items and to on the enclosed copy of a language translation o	which is enclosed, are tion of this application. Independently ascertain From PTO-1449 that is f that item or a portion			
2.		For each of the following items listed on the English language, a concise of incorporated in the specification of the	explanation of the relev	ance of that item is			
3.		Any copy of the items listed on the enc enclosed with this Information Disclos submitted to the Patent and Trademark	ure Statement was prev	iously cited by or			
4.		No fee is due under 37 C.F.R. §1.17(p) since it is being filed in compliance with		isclosure Statement			

Docket No. 4439-4028 Serial No. 10/518,870

	ш	application other than a CPA; or
		37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or
	\boxtimes	$37\ C.F.R.\ \S 1.97(b)(3),$ before the mailing date of a first Office action on the merits; or
		37 C.F.R. $\S 1.97(b)(4)$ before the mailing date of a first office action after the filing of an RCE under $\S 1.114.$
5.	since in para Allow	e is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement to the being filed in compliance with 37 C.F.R. §1.97(c), after the period specified agraph 4 above but before the mailing date of a final action or a Notice of ance (where there has been no prior final action), and is accompanied by one of rtifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.
6.	it is be paragr	is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since eing filed in compliance with 37 C.F.R. §1.97(c), after the period specified in aph 4 above but before the mailing date of a final action or a notice of unce (where there has been no prior final action):
		A check in the amount of \$180.00 is enclosed in payment of the fee.
		Charge the fee to Deposit Account No. <u>13-4500</u> , Order No A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
7.	it is be action	is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since eing filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final or a notice of allowance, whichever comes first, but before payment of the issue d is accompanied by:
		ne of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 elow; and
		e fee due under 37 C.F.R. §1.17(p) which is paid as set forth in paragraph 11 clow.
8.	This I	nformation Disclosure Statement is being filed in compliance with:
	a. 🗌	37 C.F.R. §1.313(b)(3) or §1.313(c)(1), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h);
	b. 🗌	37 C.F.R. §1.313(c)(2) or §1.313(c)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Request for Continued Examination (RCE) or a Continuation application upon abandonment of the instant amplication and is accompanied by the

attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h). c. The fee due under 37 C.F.R. §§1.17(h) is paid as set forth in paragraph 11 I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry. was known to any individual designated in \$1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 10. This document is accompanied by \omega a Search Report for corresponding European application number EP 03 73 3506. 11. A check in the amount of \$ is enclosed in payment of the fees due under 37 C.F.R. §§1.17(h) and 1.17(p). Charge the fees due under 37 C.F.R. §§1.17(h) and 1.17(p) to Deposit Account No. 13-4500, Order No. _____. X The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500, Order No. 4439-4028 Respectfully submitted. MORGAN & FINNEGAN, L.L.P. Dated: September 24, 2007 Bv: Registration No. 56,390 Correspondence Address: Address Associated With Customer Number: 27123 (212) 415-8700 Telephone (212) 415-8701 Facsimile

FORM PTO-1449A INFORMATION DISCLOSURE CITATION

Attorney Docket:	Serial No.:
4439-4028	10/718.870
Applicant: SHICHIRI, et al.	10/710,070
Filing Date:	Group Art Unit:
August 29, 2005	1614

Examiner Initial Patent/Publication Number Publication/Issue Date Name Filing Date

To Chamber	1000001	The annual to the the the total of the	1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	and side of the second	CONTRACTOR AND AND AND	And the Late of the
Examiner Initial		Patent Number	Publication Date	Country	Copy Filed	Translation
/A.P./	1.	WO 99/58126	18.11.99	PCT	⊠ Yes	☐ Yes ☐ No ☐ Abstract ☐ N/A
					☐ Yes	☐ Yes ☐ No ☐ Abstract ☐N/A
					☐ Yes	☐ Yes ☐ No ☐ Abstract ☐ N/A
					☐ Yes	☐ Yes ☐ No ☐ Abstract ☐N//
					☐ Yes	Yes No Abstract N/
					☐ Yes	☐ Yes ☐ No ☐ Abstract ☐N/

Examiner	/Anna Pagonakis/	Date Considered	10/14/2008			
EXAMINER:	Initial if reference considered, whether or not citation is in conformance with MPEP §609.					
	Draw line through citation if not in conformance and not considered.					
	Include copy of this form with next communication to Applicant.					

FORM PTO-1449B

INFORMATION DISCLOSURE CITATION

Attorney Docket:	Serial No.:	
1439-4028	10/518,870	
Applicant:		
SHICHIRI, et al.		
Filing Date:	Group Art Unit:	

1614

August 29, 2005 NON PATENT LITERATURE DOCUMENTS

NONTALENT EITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
		Communication with Supplementary European Search Report for Application	+
	1.	Number EP 03 73 3506.	+
/A.P./	2.	MALKOWSKA-ZWIERZ, "Anti-Angiogenic Effects of Some Anti-Microbial Drugs", International Journal of Oncology, vol. 7: 968, XP008050065, 1995.	1
/A.P./	3.	GIDOH et al., "Determination Of Three Main Antileprosy Drugs And Their Main Metabolites In Serum By High-Performance Liquid Chromatography", Journal of Chromatography, 223:379-392, 1981.	
/A.P./	4.		
/A.P./	5.	ACOCELLA, "Clinical Pharmacokinetics of Rifampicin", Clinical Pharmacokinetics, 3:108-127, 1978.	
			1
			-

Examiner Signature	/Anna Pagonakis/	Date Considered	09/23/2008	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional), 2 Applicant is to place a check mark here I English language Translation is attached. This collection of information is required by 20°FR 19° and 13° Bit in eleteration is required to 20°th or 20°th o